Table 1.
Overall patient characteristics
| LFP (n = 32) | Sorafenib (n = 14) | p value | |
|---|---|---|---|
| Age, years | 65 (40–81) | 68 (53–82) | 0.293 |
| Sex, male/female | 29/3 | 12/2 | 0.633 |
| PS 0/1 | 19/13 | 6/8 | 0.748 |
| Vp3/Vp4 | 25/7 | 5/9 | 0.008 |
| EHS+/EHS− | 7/25 | 5/9 | 0.567 |
| Main tumor size, mm | 74.7 (0–179.1) | 65.8 (32.7–108.0) | 0.567 |
| Tumor burden, ≤50%/>50% | 15/17 | 6/8 | 0.801 |
| Child-Pugh score 5/6 | 11/21 | 4/10 | 1.000 |
| Bilirubin, mg/dL | 0.7 (0.3–1.4) | 0.8 (0.4–1.4) | 0.781 |
| Albumin, g/dL | 3.6 (2.9–4.7) | 3.6 (3.3–4.2) | 0.706 |
| Prothrombin time, % | 82 (51–99) | 87 (51–122) | 0.142 |
| White blood cells, / µL | 4,900 (1,650–10,590) | 5,260 (2,590–7,050) | 0.830 |
| Hemoglobin, g/dL | 12.5 (8.1–15.2) | 12.3 (8.8–15.5) | 0.474 |
| Platelets, / µL | 15.7 (7.3–45.9) | 12.4 (10.6–24.3) | 0.551 |
| Etiology, HBV/HCV/NBNC | 12/7/13 | 4/8/2 | 0.0495 |
| Alpha-fetoprotein, ng/mL | 466.1 (5.1–340,140) | 416.9 (4.3–211,634) | 0.445 |
| PIVKA-II, mAU/mL | 2,570 (23–307,000) | 18,800 (414–631,000) | 0.052 |
| History of TACE, +/− | 12/20 | 9/5 | 0.117 |
| Initial dose, 400 mg/800 mg | - | 7/7 | - |
The numerical data represent the numbers of cases or the median values. Tumor burden means the relative rate of tumor occupying the liver. EHS, extrahepatic spread; HBV, hepatitis B virus; HCV, hepatitis C virus; LFP, low-dose 5-fluorouracil and cisplatin; NBNC, non-B non-C; PIVKA-II, protein induced by vitamin K absence or antagonist II; PS, performance status; TACE, transarterial chemoembolization; Vp3, tumor thrombus involving the first branches of the portal vein; Vp4, tumor thrombus involving the main trunk of the portal vein.